UNSPSC 51183403: Nateglinide

This classification denotes an anti-diabetic agent with the molecular formula C19H27NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 41X3PWK4O2, chemically known as d-phenylalanine, n-((4-(1-methylethyl)cyclohexyl)carbonyl)-, trans- but more generally known as nateglinide, which bears US NIH Compound Identifier 60026. European Medicines Agency schedules Nateglinide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09170MIG.

UNSPSC 51183403 Nateglinide, a Commodity code, encompasses pharmaceutical products—specifically branded and generic nateglinide diabetes medications—that state and local governments procure through cooperative purchasing agreements for distribution to public health facilities, correctional institutions, and other government-operated healthcare settings. Recent solicitation activity shows state and local buyers pursuing nateglinide supplies as part of broader multi-source pharmaceutical procurement vehicles that bundle dozens or hundreds of drug products into single cooperative contracts, enabling volume pricing and standardized distribution through authorized pharmaceutical wholesalers. The scope includes not only the active pharmaceutical ingredient itself but also packaging, strength, dosage form, and product metadata (NDC codes, SKUs, UPCs) necessary for inventory management and supply-chain compliance.

The primary issuing body in recent activity is the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, which issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products across participating states including Minnesota and Oregon. MMCAP's approach is representative of state and regional cooperative-purchasing consortia that consolidate demand across multiple jurisdictions to achieve pricing leverage; vendors must meet cGMP certification, Drug Supply Chain Security Act compliance, relationships with authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), and insurance requirements ($5 million general liability, $2 million network security and privacy liability, $2 million professional liability). Award is contingent on price competitiveness (weighted at 75 percent in evaluation), EDI capability, and ability to supply products with NDC codes and pricing through flat-rate, net-price, or WAC-minus structures. The contract term runs two years from July 1, 2026 with optional extensions, with vendors subject to a 3 percent administrative fee on all purchases and performance penalties of $200 to $1,500 per violation.